{
  "figure_1": "(A) Viability of BT-474Br and MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours and 48 hours. (B) Caspase-3/-7 activity in BT-474Br and MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours and 48 hours. (C) Immunofluorescence staining for cleaved caspase-3 after metixene treatment of BT-474Br cells for 2 days. Scale bars: 25 μm. (D) Immunofluorescence staining for cleaved caspase-3 after metixene treatment in MDA-MB-231Br cells for 2 days. Scale bars: 75 μm. (E) Caspase-8/-9 activity in BT-474Br cells under treatment at different concentrations of metixene for 24 hours. (F) Caspase-8/-9 activity in MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours. The results in A, B, E, and F are representative of 3 or more technical replicates, and bar graph data show the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test.",
  "figure_2": "(A) Experimental setup of mammary fat pad injections with HCC1954 cells and subsequent treatment with metixene. (B) Metixene treatment at 0.1 mg/kg and 1.0 mg/kg decreased tumor sizes in comparison with controls. (C) Tumor weight at 0.1 mg/kg and 1.0 mg/kg of metixene treatment. (D) Tumor volume at 0.1 mg/kg and 1.0 mg/kg of metixene treatment. (E) H&E (scale bar: 250 μm) and cleaved caspase-3 (scale bar: 50 μm) staining of tumors treated with control, 0.1 mg/kg, and 1.0 mg/kg metixene. Red color indicates cleaved caspase-3; blue color represents DAPI. (F) Percentage of cleaved caspase-3–positive cells (n = 3 per group). (G) Experimental setup for intracardiac injections of MDA-MB-231 cells and subsequent treatment with metixene. (H) Kaplan-Meier curve showing survival of metixene-treated mice versus control mice following intracardiac injection of MDA-MB-231 cells. (I) Experimental setup to determine the bioavailability of metixene in blood and brain tissue. (J) Metixene levels in plasma and brain tissue across time after intraperitoneal administration. **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test (C and F) 2-way ANOVA with Tukey’s post hoc test (D). Survival curves were compared using a log-rank test.",
  "figure_3": "(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A). Scale bars: 250 μm. (E) Experimental setup for intracarotid artery injection of MDA-MB-231Br cells into nude mice and subsequent treatment with metixene. (F) Kaplan-Meier curve showing survival of metixene-treated mice versus controls upon intracarotid injection of MDA-MB-231Br cells. (G) Histological brain sections upon death of the control mice confirmed the growth of brain tumors as a result of intracarotid injection of MDA-MB-231Br cells. H&E staining of mouse brain shows metastatic tumors (black-framed box), the formation of multiple micrometastases (blue-framed box), and vascular co-option (red-framed box). Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B). Scale bars: 250 μm. Survival curves were compared using a log-rank test. The linear mixed model was fitted for C, and the differences between the 2 groups for each time point were calculated using the least-squares means method and adjusted by Šidák’s method. *P < 0.05 and ***P < 0.001.",
  "figure_6": "(A) Control and metixene-treated BT-474Br and MDA-MB-231Br cells expressing mCherry-GFP-LC3. Autophagosomes display both GFP and mCherry fluorescence, appearing yellow/green. Autolysosomes showcase mCherry fluorescence only, as GFP was denatured by acidic lysosomes, appearing red. Scale bars: 20 μm. (B) Electron microscopic images of metixene-treated BT-474Br and MDA-MB-231Br cells (white arrows show double-membraned autophagosomes). Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B). Scale bars: 250 μm. Results are representative of 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test.",
  "figure_7": "(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13). Scale bars: 250 μm. Results in A–C are representative of 3 independent experiments. Results in D are representative of 8 technical replicates. Results in E are representative of 4 technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA with Šidák’s post hoc test."
}